Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + azacitidine for prevention of MRD-positive AML relapse around allo-HSCT
ChiCTR2300076815Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and azacitidine in acute myeloid leukemia (AML), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: 6-month relapse-free survival rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
tucidinostatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300076815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076815.